Co-Diagnostics JV Secures ISO 13485 Certification for Indian Manufacturing Hub
Event summary
- CoSara Diagnostics, a Co-Diagnostics JV, received ISO 13485:2016 certification for its Vadodara, India manufacturing facility on February 4, 2026.
- The certification covers the quality management system for medical device manufacturing, including the upcoming PCR platform.
- Co-Dx executives visited India to finalize software for tuberculosis and HPV tests, and to prepare manufacturing lines for commercialization.
- ISO 13485 certification is positioned as critical for regulatory clearance and participation in India's 'Make in India' initiative.
The big picture
This certification positions Co-Diagnostics to navigate India's regulatory landscape while leveraging cost advantages of domestic manufacturing. The move aligns with broader trends of diagnostic companies establishing localized production to serve high-growth emerging markets. Success will depend on executing clinical studies and securing clearances while maintaining quality standards.
What we're watching
- Regulatory Pathway
- Whether ISO 13485 certification will accelerate CDSCO and FDA clearance for the PCR platform.
- Manufacturing Costs
- The extent to which in-country manufacturing under 'Make in India' reduces platform costs versus imports.
- Commercialization Timeline
- The pace at which clinical performance studies and manufacturing readiness will enable market launch.
Related topics